Pitolisant GR
Small molecule
Evidence outlook · regulatory review
Narcolepsy: application under FDA review, decision date 2027-04-01
PDUFA date for the Pitolisant GR NDA (2027-04-01). A filing is the sponsor's claim that its evidence supports approval; this platform grades the trials, not the filing. The event is listed under Regulatory events.
How the evidence outlook works ↗
Featured trials
The studies most instrumental to this drug's clinical progression, individually graded on design and result. The complete registry, including every study not featured here, is listed below.
Featured-trial selection for this indication is pending.
All registered studies
Every ClinicalTrials.gov study of this drug's own program. Studies backing a featured trial above are marked Featured; the rest aren't individually graded.
No registered studies found. Not yet ingested, or none registered.
Competitive landscape
Other Histamine H3 receptor (antagonist / inverse agonist) drugs
Pitolisant (Wakix), ALTO-203. Compare all 3 Histamine H3 receptor (antagonist / inverse agonist) drugs
2 other tracked programmes target this mechanism.
This drug's own stage for Narcolepsy: Stage not on record. Competitors below are sorted furthest-along first.
| Drug | Stage | Modality | Mechanism | Evidence signal | Reported efficacygraded featured trials | |
|---|---|---|---|---|---|---|
| Pitolisant GR: this drug | Stage not on record | Small molecule | Histamine H3 receptor (antagonist / inverse agonist) | not yet graded | No reviewed efficacy summary in this indication | |
| Calcium, Magnesium, Potassium And Sodium Oxybates (Xywav) | Approved | Small molecule | GABA-B receptor | not yet graded | No reviewed efficacy summary in this indication | |
| Modafinil (Provigil) | Approved | Small molecule | Sympathomimetic-like Agent | not yet graded | No reviewed efficacy summary in this indication | |
| Oveporexton (Orzeyful) | Approved | Small molecule | Orexin-2 receptor (agonist) | not yet graded | No reviewed efficacy summary in this indication | |
| Pitolisant (Wakix) | Approved | Small molecule | Histamine H3 receptor (antagonist / inverse agonist) | Reliable signal | NCT02611687: To Evaluate the Efficacy of Pitolisant in Reducing Residual Excessive Daytime Sleepiness (EDS), Ullanlinna Narcolepsy Scale Score. (8 weeks): Pitolisant -6.29 score on a scale (Standard Error 1.14) | Placebo -2.6 score on a scale (Standard Error 1.35) | |
| Sodium Oxybate | Approved | Small molecule | GABA-B receptor | Partial signal | Featured results are non-efficacy only in this race | |
| Solriamfetol (Sunosi) | Approved | Small molecule | Dopamine/norepinephrine transporter | Partial signal | NCT02348632: Change in Epworth Sleepiness Scale score from the start to the end of the 2-week randomized-withdrawal period (positive = worse): +1.6 with continued solriamfetol (n=139) vs +5.3 after switch to placebo (n=141); difference -3.7 points (95% CI -4.8 to -2.7), significant after multiplicity adjustment (SUNOSI label Table 8; CT.gov posted results). NCT02348593: Change from baseline to week 12 vs placebo: MWT +12.3 (300 mg) and +9.8 (150 mg) vs +2.1 minutes; ESS -6.4 and -5.4 vs -1.6 points (all p<0.0001). The 75 mg dose (MWT +4.74, ESS -3.8) was not statistically significant on either coprimary (Thorpy et al., Ann Neurol 2019; SUNOSI label). | |
| Alixorexton | Phase 3 | Small molecule | Orexin-2 receptor (agonist) | not yet graded | No reviewed efficacy summary in this indication | |
| Reboxetine | Phase 3 | Small molecule | norepinephrine transporter | Partial signal | NCT05113745: Primary endpoint, change in frequency of cataplexy attacks in the randomized withdrawal phase: statistically significant improvement vs placebo (Axsome, 2024-11-26). | |
| Cleminorexton | Phase 2/3 | Small molecule | — | not yet graded | No reviewed efficacy summary in this indication | |
| TAK-360 | Phase 2/3 | Small molecule | Orexin-2 receptor (agonist) | not yet graded | No reviewed efficacy summary in this indication | |
| ALTO-203 | Phase 2(overall) | Small molecule | Histamine H3 receptor (antagonist / inverse agonist) | Partial signal(overall) | No reviewed efficacy summary in this indication |
Compare side by side
Upcoming events
No upcoming readouts on record for this asset.
Regulatory and conference events
(2)
Filings, regulator decisions, scientific presentations, topline results and licensing deals, each from a dated source. When a source gives only the month, the month is shown.
Coming up
Recent